Leisl Packer

Transcriptional Pathway Signatures Predict MEK Addiction and Response to Selumetinib (AZD6244)

Jonathan R. Dry, Sandra Pavey, Christine A. Pratilas et al. · Cancer Research · 2010 · 264 citations · Full text

Medicine, Oncology, Pharmacology +17

Activation of the MAPK pathway is a common event in uveal melanomas although it rarely occurs through mutation of BRAF or RAS

Wieke Zuidervaart, Frans van Nieuwpoort, Mitchell Stark et al. · British Journal of Cancer · 2005 · 217 citations · Full text

Medicine, Molecular Biology, Oncology +17

Oncogenic BRAF Induces Melanoma Cell Invasion by Downregulating the cGMP-Specific Phosphodiesterase PDE5A

Imanol Arozarena, Berta Sanchez‐Laorden, Leisl Packer et al. · Cancer Cell · 2011 · 210 citations

Life Sciences, Molecular Biology, Oncology +9

Microarray expression profiling in melanoma reveals a BRAF mutation signature

Sandra Pavey, Peter A. Johansson, Leisl Packer et al. · Oncogene · 2004 · 184 citations

Life Sciences, Molecular Biology, Oncology +16

Nilotinib and MEK Inhibitors Induce Synthetic Lethality through Paradoxical Activation of RAF in Drug-Resistant Chronic Myeloid Leukemia

Leisl Packer, Sareena Rana, Robert Hayward et al. · Cancer Cell · 2011 · 125 citations · Full text

Medicine, Oncology, Pharmacology +14